FDA has granted a Priority Review for tocilizumab (Actemra) intravenous for the treatment of hospitalised COVID-19 adults receiving systemic corticosteroids and require supplemental O2, mechanical ventilation, or ECMO. https://t.co/b4GSuvsElp https://t.co/oEGskAJVyd

COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/Hc4rNrlQzP https://t.co/UPosZIc4C0

Deucravacitinib, TYK2 inhib, studied in phase II trial 203 active PsA pts randomised to PBO, or DEUC 6 mg or 12 mg qd. At wk 16 ACR-20 responses were significantly higher with DEUC 6mg (53%, p=0.0134) and 12 mg (63%, p=0.0004) vs PBO. https://t.co/0nvutsXHsI https://t.co/jh43zCbdZx

Differences between Palpated & Ultrasound Joint exams in 155 #PSA patients. 5616 joints - found 18.5% tender, 9.8% swollen, 20.4% w/ US GS ≥ 2 and 5.2% had US PD ≥ 1. Joints that were both tender and swollen more likely to have GS ≥ (44%) https://t.co/nWI7jLdkWp https://t.co/iRNsqWYScM

Rheum Comanagement of Psoriasis https://t.co/vXF4t2IIoW QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/fDVx49XtYP

“Do as much as possible for the patient, & as little as possible to the patient.” (B Lown). JAMA review of Antithrombotics in COVID-19 says all hospitalized COVID pts with COVID-19 should recv anticoagulation with heparin; no proven value to anti-Plts Rx https://t.co/ZfaH4FiRy1 https://t.co/DW8BGKjfnX

Dactylitis Indicates a Severe PsA Phenotype https://t.co/bUg15czr1Q https://t.co/bnawRJ20jj

Among 1033 #PSA pts - 37% were obese. Obese PsA pts had higher PsAQoL, HADS-Anxiety, HADS-Depression, DAPSA, DAS28-CRP, BASDAI, BASFI, HAQ &FACIT scores (p<0.05). BMI affects QOL, depression, disease activity, fatigue https://t.co/6PD8G6xFnk https://t.co/Wlgp0gJGbK

This week's Daily Download includes 9 slides covering Moll & Wright classification; epidemiology & prevalence; factors; skin & joint images, and more. https://t.co/Pr7vODmmnr https://t.co/TEzUy5r4rZ

Australian study from 2 #PSA clinics PsA clinics compared RAPID3 score to MDA, very low disease activity (VLDA) & DAPSA. 93 pts showed RAPID3 correlated w/ ROC AUC for VLDA (0.94) and DAPSA (0.96) https://t.co/x9G8wTpeS6 #PsAlways https://t.co/WuseKMoiJj

QD Clinic - PsA Lessons from the Clinic Does the Moll & Wright Classification of PsA hold up? QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/zskcsZ4kkW https://t.co/QZOb09wGyp

Czech registry compared drug survival csDMARDs vs TNFi monotherapy. Drug retention higher w/ combo (47 vs 23 mos; p < 0.001) than TNFi monotherapy. 5 yr survival was better 45% vs 26%; Combo w/ MTX > other csDMARDs (p = 0.003). https://t.co/pjbXwEQ53K https://t.co/nZj64Wk3Pt